Paul Kaye

Paul Kaye

Professor of Immunology 

University of York, UK

Tel: +44 (0)1904 328840

Email: Paul.Kaye@york.ac.uk

 

 

 

VALIDATE Role:

Network Investigator

 

Research Keywords: 

Immunology & infectious diseases; Leishmaniasis; vaccines; disease pathology

 

Biography:

Paul Kaye is Professor of Immunology at the University of York. He trained in zoology (BSc) and immunology (PhD) and has worked for over 30 years on the immunology and immunopathology of the neglected tropical disease leishmaniasis. He is internationally recognized for his research on macrophages and dendritic cells, contributing to a fundamental understanding of their biology in health and disease, and for his work on lymphoid tissue remodelling and granulomatous inflammation during chronic infection. Paul is a Wellcome Senior Investigator and an elected Fellow of the UK Academy of Medical Sciences. He was awarded FRCPath by publication in 2004 and has published over 150 articles and reviews, with numerous articles in leading international journals (e.g. Nature Medicine, Immunity, J. Clin. Invest., PNAS). Paul’s research tackles leishmaniasis from a holistic viewpoint, rooted in the immunology of the host-parasite interaction, but employing tools and approaches taken from many disciplines, including mathematics, ecology, vector biology and neuroscience. He has extensive links with leishmaniasis-endemic countries and is currently leading a Phase II therapeutic vaccine trial in Sudan and developing a digital pathology platform to facilitate a greater understanding of disease pathogenesis through data sharing and collaboration across geographic borders.

 

Related Websites: 

Profile page at University of York

University of York Research Database

 

Key Publications:

Osman, M., Mistry, A., Keding, A., Gabe, R., Cook, E., Forrester, S., Wiggins, R., Di Marco, S., Colloca, S., Siani, L., Cortese, R., Smith, D.F., Aebischer, T., Kaye, P.M*. and Lacey C.J.  (2017) A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH. PLoS Negl Trop Dis. 11(5):e0005527. (*co-corresponding author) PMID: 28498840

Pinto, A.I., Brown, N., Preham, O., Doehl, J.S.P., Ashwin, H. and Kaye, P.M. (2017) TNF signalling drives expansion of bone marrow CD4+ T cells responsible for HSC exhaustion in experimental visceral leishmaniasis. PLoS Pathog. 13(7):e1006465. PMID:28671989

Doehl, J.S.P., Bright, Z., Dey, S., Davies, H., Magson, J., Brown, N., Romano, A., Dalton, J.E., Pinto, A.I., Pitchford, J.W and Kaye, P.M.  (2017) Skin parasite landscape determines host infectiousness in visceral leishmaniasis. Nature Comm. 57: doi:10.1038/s41467-017-00103-8  PMID: 28680146